Worth Asset Management’s ImmunityBio IBRX Stock Holding History

Worth Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,550	Closed	-$4.31K	–	235
2023 Q2	$4.31K	Hold	1,550	–	–	﹤0.01%	371
2023 Q1	$2.82K	Hold	1,550	–	–	﹤0.01%	411
2022 Q4	$7.86K	Hold	1,550	–	–	0.01%	324
2022 Q3	$8K	Sell	1,550 -100	-6%	-$456	0.01%	299
2022 Q2	$6K	Hold	1,650	–	–	﹤0.01%	392
2022 Q1	$5K	Buy	+1,650	New	+$10.1K	﹤0.01%	402

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Worth Asset Management's IBRX Position: Q3 2023 in Review

Worth Asset Management sold out of ImmunityBio (IBRX) in Q3 2023, closing a stake of 1,550 shares — an estimated $4.31K sold.

Worth Asset Management first reported a position in IBRX in Q1 2022 and held it in 6 quarters. The position peaked at $8K in Q3 2022. 131 funds tracked by Wall St. Rank hold IBRX as of Q3 2023.

Worth Asset Management reported no remaining ImmunityBio position as of Q3 2023 after selling out during the quarter.
Worth Asset Management sold 1,550 ImmunityBio shares in Q3 2023, an estimated $4.31K.
Worth Asset Management first reported a position in ImmunityBio in Q1 2022 and held it in 6 quarters.
Worth Asset Management's ImmunityBio position peaked at $8K in Q3 2022.
131 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2023.

Based on Worth Asset Management's 13F filing for Q3 2023, filed 11 Oct 2023.